PTI-2

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
PTI-2
PTI-2 structure.png
Systematic (IUPAC) name
N-(2-methoxyethyl)-N-((2-(1-pentyl-1H-indol-3-yl)thiazol-4-yl)methyl)propan-2-amine
Clinical data
Legal status
Identifiers
CAS Number 1400742-45-1
Chemical data
Formula C23H33N3OS
Molecular mass 399.60 g/mol
  • CCCCCN1C=C(C2=NC(CN(CCOC)C(C)C)=CS2)C3=CC=CC=C31.Cl
  • InChI=1S/C23H33N3OS.ClH/c1-5-6-9-12-26-16-21(20-10-7-8-11-22(20)26)23-24-19(17-28-23)15-25(18(2)3)13-14-27-4;/h7-8,10-11,16-18H,5-6,9,12-15H2,1-4H3;1H
  • Key:CTUGBODVZGSSRI-UHFFFAOYSA-N

PTI-2 is an indole-based synthetic cannabinoid.[1] It is one of few synthetic cannabinoids containing a thiazole group and is closely related to PTI-1. These compounds may be viewed as simplified analogues of indole-3-heterocycle compounds originally developed by Organon and subsequently further researched by Merck.[2][3][4][5]

See also

References

<templatestyles src="Reflist/styles.css" />

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This cannabinoid related article is a stub. You can help Wikipedia by expanding it.
  1. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ Julia Adam-Worrall, et al. (Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor. Patent US 7700634, priority date 5 March 2004
  3. ↑ Paul David Ratcliffe, et al. Indole Derivatives. Patent US 7763732, priority date 24 August 2005
  4. ↑ Julia Adam, et al. Indole Derivatives. Patent WO 2008/101995, priority date 22 February 2007
  5. ↑ Takao Kiyoi, et al. Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists. Bioorganic and Medicinal Chemistry Letters 2011; 21(6):1748-1753. doi: 10.1016/j.bmcl.2011.01.082
Retrieved from "https://infogalactic.com/w/index.php?title=PTI-2&oldid=713236684"